Dermatan Sulfate-based Drug-Delivery Vehicle Development Service

Dermatan sulfate (DS) is a linear polysaccharide formed by the connection of hexosamine (consisting of N-acetylgalactosamine or glucuronic acid). DS has a negative charge and effectively maintains good stability and biocompatibility in the circulating system. CD BioGlyco provides DS-based drug-delivery vehicle development services based on this feature. Moreover, we provide high-targeting Chondroitin Sulfate, Heparan Sulfate, and Keratan Sulfate-based drug-delivery vehicle development services. The purpose of changing its drug-delivery vehicle properties is achieved by changing the molecular weight, composition, purification degree, attachment side group, and molecular conformation.

DS-based Drug-Delivery Vehicle Development Service at CD BioGlyco

Preparation and Characterization Service

Our synthesis team prepares DS-based drug-delivery vehicles at room temperature by ion crosslinking method. We provide particle size, monodispersity, and zeta potential detection services of nanoparticles through dynamic light scattering (DLS) or electric field. Furthermore, we provide morphological observation services.

In Vitro Activity Analysis Service

In Vivo Bioactive Service

• Animal model: According to the needs of the clients, we provide disease mouse model-building services. The disease model is constructed by subcutaneous injection and the disease onset is observed on time.
• Pharmacokinetic assay: After a period of treatment, we use high-performance liquid chromatography (HPLC) to quantify the drug content in the blood. Furthermore, we offer drug biodistribution identification services in major tissues.
• Other services: We provide efficacies assay service and myelosuppression detection service.

Fig.1 Schematic illustration of DS-based drug-delivery vehicle synthesis and analysis. (CD BioGlyco)

Publication

Technology: MTT, UV-vis spectrophotometry, Flow cytometry

Journal: Carbohydrate polymers

Published: 2020

IF: 11.2

Results: In this article, DS-functionalized chitosan nanoparriarrier (DCNP) was synthesized for the use of melanoma-targeted therapy. DS to the surface of glycan nanocarriers (CNP) by amide bonding. Under acidic conditions, they effectively release anti-tumor drugs. Flow cytometry showed that DS functionalization improved the uptake capacity of nanocarriers by cluster of differentiation 146 (CD146) tumor cells. DCNP showed significant tumor-targeting effects in an in vivo model. DCNP has similar CD146 bonding properties with proteoglycans and is efficiently regulated by targeted therapy.

Fig.2 Cellular uptake profiles of NPs by B16F10 melanoma cells. (Li, et al., 2020)

Applications

• DS-based drug-delivery vehicle binds efficiently to melanoma cells with high expression of CD146.
• DS-based drug-delivery vehicles downregulate the activity of the oncoprotein erb-B2 and induce the upregulation of the tumor suppressor gene p21, thereby blocking the cell cycle.
• DS-based drug-delivery vehicle significantly increases the targeted enrichment at tumor sites and has better inhibitory effects on tumor volume.

Advantages of Us

• The DS-based drug-delivery vehicle we provide has the advantages of prolonging drug circulation time, continuously releasing drugs, and improving drug efficacy.
• Our researchers constantly adjust the synthesis parameters to achieve the purpose of uniform morphology, high drug loading rate, and high encapsulation rate.

CD BioGlyco has a professional development team and advanced instruments to provide Marine Carbohydrate-based Drug-Delivery Vehicle development services. In addition, we also provide high-level marine carbohydrate-based Vaccine, Adjuvant, and Biomarker development. Our researchers strictly grasp the time required to deliver drug molecules to a specific tissue or region, and the ability of controlled drug release. Please feel free to contact us.